Literature DB >> 16236628

Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

E M Horwitz1, K Le Blanc, M Dominici, I Mueller, I Slaper-Cortenbach, F C Marini, R J Deans, D S Krause, A Keating.   

Abstract

The plastic-adherent cells isolated from BM and other sources have come to be widely known as mesenchymal stem cells (MSC). However, the recognized biologic properties of the unfractionated population of cells do not seem to meet generally accepted criteria for stem cell activity, rendering the name scientifically inaccurate and potentially misleading to the lay public. Nonetheless, a bona fide MSC most certainly exists. To address this inconsistency between nomenclature and biologic properties, and to clarify the terminology, we suggest that the fibroblast-like plastic-adherent cells, regardless of the tissue from which they are isolated, be termed multipotent mesenchymal stromal cells, while the term mesenchymal stem cells is used only for cells that meet specified stem cell criteria. The widely recognized acronym, MSC, may be used for both cell populations, as is the current practice; thus, investigators must clearly define the more scientifically correct designation in their reports. The International Society for Cellular Therapy (ISCT) encourages the scientific community to adopt this uniform nomenclature in all written and oral communications.

Mesh:

Year:  2005        PMID: 16236628     DOI: 10.1080/14653240500319234

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  558 in total

Review 1.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

2.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

3.  Current Regulations for the Production of Multipotent Mesenchymal Stromal Cells for Clinical Application.

Authors:  Ineke C M Slaper-Cortenbach
Journal:  Transfus Med Hemother       Date:  2008-07-21       Impact factor: 3.747

4.  Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease - Implications for Clinical Applications and Donor Recruitment.

Authors:  Günter Lepperdinger; Regina Brunauer; Robert Gassner; Angelika Jamnig; Frank Kloss; Gerhard Thomas Laschober
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 5.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 6.  Renal repair: role of bone marrow stem cells.

Authors:  Fangming Lin
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

7.  Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells.

Authors:  Simon Lord-Dufour; Ian B Copland; Louis-Charles Levros; Martin Post; Abhirup Das; Chaitan Khosla; Jacques Galipeau; Eric Rassart; Borhane Annabi
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

Review 8.  Mesenchymal Stem Cell Therapy for Cutaneous Wounds.

Authors:  Anne M Hocking
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-08       Impact factor: 4.730

9.  Comparison of tenocytes and mesenchymal stem cells seeded on biodegradable scaffolds in a full-size tendon defect model.

Authors:  M F Pietschmann; B Frankewycz; P Schmitz; D Docheva; B Sievers; V Jansson; M Schieker; P E Müller
Journal:  J Mater Sci Mater Med       Date:  2012-10-23       Impact factor: 3.896

Review 10.  Mesenchymal stem cell treatments in rheumatology: a glass half full?

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.